ArticleThe Journal of experimental medicine2019
PIP4K2A as a negative regulator of PI3K in PTEN
Open access · hybridAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- PIP4K2A: A Novel CD8+ T Cell-Related Biomarker Associated with Lung Function Decline in COPD.Biochemical genetics · 2026Article
- A proximity-labeling map of PI5P4K phosphoinositide kinases interaction networks.The Journal of biological chemistry · 2026Article
- Article
- PI5P4K inhibitors: promising opportunities and challenges.The FEBS journal · 2025Review
- Downregulation of PIP4K2C inhibits the breast cancer cell proliferation, migration and invasion.Translational oncology · 2025Article
- Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities.Nature reviews. Cancer · 2025Review
- Integrating Hypoxia Signatures from scRNA-seq and Bulk Transcriptomes for Prognosis Prediction and Precision Therapy in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.International journal of molecular sciences · 2025Article
- The epigenetic mechanisms involved in the treatment resistance of glioblastoma.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Exploring new mechanisms in cancer molecular pathways and pathogenic cell transformation: PIP4K2A as a prognostic marker and therapeutic target in cutaneous malignant melanoma.Discover oncology · 2024Article
- Exploring the Potential Role of Oligodendrocyte-Associated PIP4K2A in Alzheimer's Disease Complicated with Type 2 Diabetes Mellitus via Multi-Omic Analysis.International journal of molecular sciences · 2024Article
- A comprehensive analysis of minimally differentially methylated regions common to pediatric and adult solid tumors.NPJ precision oncology · 2024Article
- Prognostic prediction using a gene signature developed based on exhausted T cells for liver cancer patients.Heliyon · 2024Article
- Metabolic Enzyme SLC27A5 Regulates PIP4K2A pre-mRNA Splicing as a Noncanonical Mechanism to Suppress Hepatocellular Carcinoma Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine.Cancers · 2023Article
- The rational design of ARUK2007145, a dual inhibitor of the α and γ isoforms of the lipid kinase phosphatidylinositol 5-phosphate 4-kinase (PI5P4K).RSC medicinal chemistry · 2023Article
- Genes of Predisposition to Childhood Beta-Cell Acute Lymphoblastic Leukemia in the Kazakh Population.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Beyond PI3Ks: targeting phosphoinositide kinases in disease.Nature reviews. Drug discovery · 2023Review
- PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition.Science advances · 2023Article
- Modelling PIP4K2A inhibitory activity of 1,7-naphthyridine analogues using machine learning and molecular docking studies.RSC advances · 2023Article
- Targeting phosphoinositide signaling in cancer: relevant techniques to study lipids and novel avenues for therapeutic intervention.Frontiers in cell and developmental biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Yong Jae ShinInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Jason K SaInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.ORCID 0000-0002-3251-5004
Yeri LeeInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Donggeon KimInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Nakho ChangYuhan Research Institute, Yongin, Korea.
Hee Jin ChoInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Miseol SonInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Michael Y T OhInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY.
Kayoung ShinInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Jin-Ku LeeInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Jiwon ParkInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Yoon Kyung JoInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Misuk KimInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Patrick J PaddisonHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Vinay TergaonkarDivision of Cancer Cell Signaling, Institute of Molecular and Cell Biology, Singapore.ORCID 0000-0001-9009-0844
Jeongwu LeeDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH leej7@ccf.org.ORCID 0000-0002-5973-0687
Do-Hyun NamInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea nsnam@skku.edu.ORCID 0000-0002-8477-6791
Samsung Medical Center · KRSamsung (South Korea) · KRColumbia University Irving Medical Center · USFred Hutch Cancer Center · USNational University of Singapore · SGYuhan University · KR
Funding
Targeting oncogenic dopamine receptor signaling in glioblastomaR01CA223370 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LEE, JEONGWU · 2019 to 2023
$2.4MMYC-dependent loss of splicing fidelity in Glioblastoma multiformeR01CA190957 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PADDISON, PATRICK · 2015 to 2019
$2.2MPolycomb and Cellular Hierarchy in the BrainR01NS082312 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI LEE, JEONGWU · 2013 to 2017
$1.7MCooperating pathways in glioblastoma stem cellsR56NS095822 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI LEE, JEONGWU · 2017 to 2017
$400kNCI NIH HHS R01 CA190957NCI NIH HHS R01 CA223370NINDS NIH HHS R01 NS082312NINDS NIH HHS R56 NS095822
Abstract
Glioblastoma
Indexed as
AnimalsBrain NeoplasmsCarcinogenesisCell ProliferationCells, CulturedClass Ia Phosphatidylinositol 3-KinaseFemaleGlioblastomaHeterograftsHumansMiceMice, Inbred BALB CMice, NudePhosphotransferases (Alcohol Group Acceptor)PTEN PhosphohydrolaseRNA InterferenceClass Ia Phosphatidylinositol 3-KinasePhosphotransferases (Alcohol Group Acceptor)PIP4K2A protein, humanPTEN PhosphohydrolasePTEN protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.